Company intelligence / Profile preview
Raft Pharmaceuticals
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Raft Pharmaceuticals is developing RFT1081, a recombinant protein targeting cholesterol trafficking in lipid rafts of inflamed glia and macrophages, with animal studies showing efficacy in models of chemotherapy- and nerve injury-induced neuropathic pain and migraine. The approach aims to normalize lipid raft microdomains implicated in chronic pain pathology, and recent preclinical data highlight normalization of cholesterol metabolism in spinal microglia as a potential mechanism of action.
- Therapeutic areas
- Neurology
- Modalities
- Recombinant proteinProtein
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Raft Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Raft Pharmaceuticals.